Our Team
Eupraxia is proud of its experienced team of life science professionals.
Learn More
Our Lead Candidate
EP-104 is designed to address significant unmet medical need and market demand for conditions where long-lasting symptom relief is essential to effective treatment. The primary targets for EP-104 have been identified as knee osteoarthritis (OA) and eosinophilic esophagitis (EoE).
Learn More
Our Pipeline
Our technology platform may be suitable for a wide range of indications and drugs that could be improved by locally targeted and extended release.
Learn More